Robert Driscoll
Stock Analyst at Wedbush
(2.14)
# 2,726
Out of 4,711 analysts
155
Total ratings
33.8%
Success rate
-2.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $25.61 | +103.05% | 9 | Dec 17, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $67 | $44.06 | +52.07% | 4 | Dec 6, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $14.00 | +100.00% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.22 | +620.72% | 10 | Oct 8, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $15.50 | +93.55% | 7 | Oct 3, 2024 | |
| IGMS IGM Biosciences | Maintains: Outperform | $25 → $22 | $6.90 | +218.84% | 10 | Oct 1, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $85 → $51 | $13.00 | +292.31% | 1 | Sep 20, 2024 | |
| ACET Adicet Bio | Reiterates: Outperform | $5 | $0.91 | +449.45% | 8 | Sep 20, 2024 | |
| CGEM Cullinan Therapeutics | Reiterates: Outperform | $36 | $11.60 | +210.34% | 4 | Sep 18, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Outperform | $11 | $6.93 | +58.73% | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.05 | +260.66% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $4 | $3.00 | +33.33% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $37 | $9.01 | +310.65% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.14 | +152.92% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $3.10 | +319.35% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $56.83 | +30.21% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $0.84 | +1,333.86% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.38 | +479.71% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $18.48 | +208.44% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $3.49 | +100.57% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $1.09 | +633.94% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.58 | +1,279.31% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $12.49 | +316.33% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $12.79 | +173.65% | 5 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.59 | +466.04% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.21 | +24.61% | 4 | May 19, 2020 |
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $25.61
Upside: +103.05%
Revolution Medicines
Dec 6, 2024
Maintains: Outperform
Price Target: $70 → $67
Current: $44.06
Upside: +52.07%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $14.00
Upside: +100.00%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.22
Upside: +620.72%
Arcus Biosciences
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $15.50
Upside: +93.55%
IGM Biosciences
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $6.90
Upside: +218.84%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $13.00
Upside: +292.31%
Adicet Bio
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.91
Upside: +449.45%
Cullinan Therapeutics
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $11.60
Upside: +210.34%
Monte Rosa Therapeutics
Sep 12, 2024
Reiterates: Outperform
Price Target: $11
Current: $6.93
Upside: +58.73%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.05
Upside: +260.66%
Aug 12, 2024
Upgrades: Neutral
Price Target: $4
Current: $3.00
Upside: +33.33%
Aug 9, 2024
Reiterates: Outperform
Price Target: $37
Current: $9.01
Upside: +310.65%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.14
Upside: +152.92%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $3.10
Upside: +319.35%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $56.83
Upside: +30.21%
Aug 7, 2024
Reiterates: Outperform
Price Target: $12
Current: $0.84
Upside: +1,333.86%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.38
Upside: +479.71%
Jul 31, 2024
Reiterates: Outperform
Price Target: $57
Current: $18.48
Upside: +208.44%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $3.49
Upside: +100.57%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $1.09
Upside: +633.94%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.58
Upside: +1,279.31%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $12.49
Upside: +316.33%
Nov 7, 2023
Maintains: Outperform
Price Target: $39 → $35
Current: $12.79
Upside: +173.65%
Aug 24, 2023
Initiates: Outperform
Price Target: $9
Current: $1.59
Upside: +466.04%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.21
Upside: +24.61%